Disease & Cancer Genetics
Research and Development
Virtual trial Design / Real-World Evidence
Post Market Surveillance
Digital Research and Life Sciences
Our mission is to ensure that therapeutics and vaccines developed within the life science industry factor in every patient ethnicity and demographics to bolster product efficacy, health equity, and effective patient outcomes.
At Rubix LS, we deliver the data, research, and case management solutions to help life science companies target and address these problems from the onset to ensure that we shorten the gap between delivering highly effective and all-inclusive, product innovations while ensuring inclusivity of all patient populations, equally receive the lifesaving benefits needed in today’s world.
Our focus is simple: Patient Innovation First. Always.
Data. Absolute. Auditable. Accurate
We’re putting the power of science, data, intelligence, and discovery at work for you in one transparent process. Sponsors, CROs, clinicians, patients and payers are looking for more than just healthcare options – it’s all about healthcare outcomes. See how the data we provide, merged with Artificial Intelligence and Machine Learning, are powering outcomes to be more inclusive and designing inclusive structures to bring wider demographics into therapeutic data sets.
Disease & Cancer Genetics
Drive knowledge of how patient demographics, environmental factors, and patient biological maps intersect on understanding disease behaviors and patient profiles.
Research and development
Use our AI/ML-driven process to accelerate your lead asset development efforts and reduce the time of discovery by 31%*
Real world evidence / virtual clinical trials
Our data harmonizes both historical and situational data sets that will equip your clinical teams to create targeted approaches for clinical trial success. We then drive efforts to create virtual and hybrid clinical trials in coordination with CRO’s and provider networks.
Post Market surveillance
Often overlooked, Phase IV trial adherence are essential to the long-term viability of the product. 20-30% of clinical trials are accurately represented with conducting and concluding Phase IV trials to inform public and private stakeholders for product efficacy. Use our data to drive a feedback loop to continue effective product development efforts.
Also supporting the federal markets.
As the world shifts to defend against new emerging health threats, government agencies are grappling with new ways to overcome those challenges. Agile convergence of digital and scientific innovation becomes a crucial vehicle to deliver outcomes-based approaches to achieve mission objectives.
We’re not just innovators, we’re also creating the entrepreneurial structure into agencies that will increase strength and expansion into programs that will catapult science and technology forward.
Latest News & Articles
Rubix LS on Pharma Tech Outlook
Recently our Founder and CEO, Reginald Swift, sat down with the team at Pharma Tech Outlook magazine to discuss the changes happening with the pharma industry and how digital health, particularly virtual clinical trials are mobilizing access of pipeline therapeutics...
Health Data in the COVID-19 Crisis: How racial equity is widening for patients to gain access to treatment.
The coronavirus pandemic has placed extraordinary demands on the healthcare industry and the groups that are interconnected with the healthcare industry. The strain on obtaining adequate resources to establish a baseline of trending symptomatic patients and severity...
Rubix LS Is Supporting The Federal COVID-19 Response.
Rubix LS has joined the federal consortium of industry partners to fully develop plans and strategies for mobilizing robust response measures toward the growing COVID-19 worldwide pandemic in the United States. Rubix LS is joined by countless other firms, within the...